The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…
The need for a data-driven culture in life sciences: What you don’t know can hurt you
Preventing sudden failures and unexpected downtime in life sciences organizations starts with promoting a data-driven culture across the enterprise. Promoting a data-driven culture across the enterprise is what makes today’s most successful life sciences organizations stand out. Efficient operations are only possible when the processes underlying those activities are functional, and this type of reliable…
The impact of the Virginia life sciences boom on pharmaceutical manufacturing
Virginia is emerging as a hotspot for pharmaceutical manufacturing, attracting a growing number of industry players. The privately-held pharma manufacturing organizations Civica and Phlow have a presence in the state, as do Big Pharma heavyweight Merck & Co. (NYSE:MRK) and AMPAC Fine Chemicals (NYSE:AMPA). The latter company produces active pharmaceutical ingredients and intermediates for the…